PubMed Health⌕ Search

PubMed · 8062330

[Thoughts on insulin therapy].

Abstract

The submitted review concentrates on several important features of contemporary insulin treatment of diabetes (1). Only in the minority of cases, and only in insulin-dependent diabetes typical substitution treatment is involved. Even if it approaches physiological conditions, either by a permanent insulin supply beneath the skin by means of a pump, or using the tactics of several injections per day in the system called "basal bolus", it differs from the latter by the fact that it supplies insulin first into the peripheral circulation and not into the liver and does no imitate the pulsatile character of insulin secretion (2). Contemporary insulin preparations imitate only imperfectly the physiological rapid post-prandial rise of insulinaemia with a subsequent rapid drop. In an attempt to approach this as closely as possible various insulin analogues are used and substitution of amino acids in its molecules by others (3). The antibody formation against insulin was restricted to a great extent by the introduction of mono-component insulin but was not eliminated even when biosynthetic human insulin is used. The importance of these antibodies is, however, in common cases small and is manifested by a prolonged period of action (4). Non-substitutional insulin administration in non-insulin dependent diabetes is indicated where without it satisfactory compensation of diabetes is not achieved. There are favourable reports on combined treatment with insulin and oral antidiabetics in this type. The risk are in particular undesirable body weight increments.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Páv. 1994-06-27. [Thoughts on insulin therapy].. https://pubmed.ncbi.nlm.nih.gov/8062330/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Pancreatin therapy in patients with insulin-treated diabetes mellitus and exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations. Results of a prospective multi-centre trial.

BACKGROUND: Recently, high prevalence of exocrine dysfunction in diabetic populations has been reported. Patients with fecal elastase 1 concentration (FEC) <100 microg/g have also been demonstrated to suffer from steatorrhea in about 60% of cases, indicating the need of pancreatic enzyme replacement therapy. Until now, there have only been a few reports on the use of enzyme replacement therapy in diabetic patients with exocrine pancreatic insufficiency. This investigation was designed to evaluate the impact of enzyme-replacement therapy on glucose metabolism and diabetes treatment in a prospective study of insulin-treated patients with diabetes mellitus. METHODS: A total of 546 patients with diabetes mellitus requiring insulin treatment were screened for exocrine dysfunction by FEC measurements. One hundred and fifteen patients (21.1%) had FEC <100 microg/g (normal >200 microg/g). Of these, 95 patients entered the study and 80 patients were randomized to receive either pancreatin (Creon) (39 patients) or placebo (41 patients) in a double-blind manner. Parameters of glucose metabolism, diabetes therapy and clinical symptoms were recorded in standardized protocols for 16 weeks. RESULTS: During the observation phase of 16 weeks, there were no significant differences between both groups concerning HbA(1c), fasting glucose levels, 2-h pp glucose levels, clinical parameters and safety parameters. A reduction in mild and moderate hypoglycemia was observed in the pancreatin group at the end of the study. CONCLUSIONS: Pancreatin therapy can be used safely in patients with diabetes mellitus and exocrine dysfunction. Parameters of glucose metabolism were not improved by enzyme replacement therapy.

Diabetes Mellitus, Type 1↗